Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

FDA Unveils Pilot Program to Expand Access to Investigational Oncology Drugs

Web Exclusives - ASCO Highlights

The FDA has announced the launch of an oncology-specific pilot program for physicians and patients who need access to investigational therapies. The expanded access pilot program is a concierge service, said Richard Pazdur, MD, Director, FDA’s Oncology Center of Excellence, who spoke at a press conference at the 2019 American Society of Clinical Oncology Annual Meeting.

Project Facilitate is a 2-pronged program offered by the FDA’s Oncology Center of Excellence. It includes an online resource known as an expanded access navigator, which is provided by the Reagan-Udall Foundation for the FDA. The goal of expanded access programs is to locate investigational agents for patients who typically have exhausted all other treatment options and are not able to enroll in clinical trials of these newer therapies.

According to Dr Pazdur, the FDA receives approximately 1000 expanded access requests each year. Many of these requests come from patients who are in dire need of treatment and perceive investigational therapies are a last resort. Project Facilitate will streamline the process for patients and physicians to gain access to investigational agents as well as enable the FDA to gather data to improve the expanded access process and gain more knowledge about investigational agents, including outcomes and adverse events.

The Expanded Access Navigator is a searchable database that physicians and patients can use to identify clinical trials of investigational agents. The database will also provide information about expanded access oncology programs that will expedite an information search, said Ellen V. Sigal, PhD, Board Chair, Reagan-Udall Foundation, Washington, DC.

“For the first time, those who need quick access to drug availability and expanded access options will find it in one place without having to visit site by site or sift through thousands of studies that don’t [serve] their needs,” Dr Sigal explained.

The plan is to have physicians first visit the Reagan-Udall Foundation site and then go to Project Facilitate, which expedites the physicians’ process of applying for expanded access from drug companies. This process should be more streamlined than in the past, with the FDA focusing on broadening access and following up with physicians about outcomes.

“Experienced FDA oncology staff will be available to support physicians and other healthcare professionals with their questions, assist in filling out the appropriate paperwork and [facilitate] the process,” noted Dr Pazdur in a statement from the FDA’s Oncology Center of Excellence.

The FDA plans to share outcomes and adverse events of patients who have received investigational oncology drugs through the new expanded access process with the companies that provide the drug.

Expanded access depends on the drug company’s agreement to make an investigational therapy available outside of a clinical trial. A drug company may deny such requests because of limited drug supplies and other reasons that are beyond the control of the FDA, Dr Pazdur said.

Related Items
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Phoebe Starr
Web Exclusives published on November 3, 2020 in ESMO Highlights
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
Phoebe Starr
Web Exclusives published on August 17, 2020 in AACR Highlights
ASCO 2020 Lung Cancer Highlights
Conference Correspondent  published on July 30, 2020 in ASCO Highlights
Clinical Activity of the RET Inhibitor Pralsetinib (BLU-667) in Patients with RET-Altered Solid Tumors
Conference Correspondent  published on June 10, 2020 in ASCO Highlights
Clinical Activity of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion–Positive NSCLC
Conference Correspondent  published on June 10, 2020 in ASCO Highlights
AcceleRET Lung: A Phase 3 Study of Pralsetinib in Patients with RET Fusion–Positive Metastatic NSCLC
Conference Correspondent  published on June 10, 2020 in ASCO Highlights
Efficacy of Capmatinib in Second-Line Treatment of Patients with METex14-Mutated NSCLC
Conference Correspondent  published on June 10, 2020 in ASCO Highlights
Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors
Conference Correspondent  published on June 10, 2020 in ASCO Highlights
Next-Generation RET Inhibitor TPX-0046 Is Active in Drug-Resistant and Naïve RET-Driven Cancer Models
Conference Correspondent  published on June 10, 2020 in ASCO Highlights
Antitumor Activity of Selpercatinib (LOXO-292) in Patients with RET-Mutant Medullary Thyroid Cancer
Conference Correspondent  published on June 10, 2020 in ASCO Highlights
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.